Management of benign prostatic hyperplasia: Defining the role of tamsulosin

Disease Management and Health Outcomes

Volumn 12, Issue 5, 2004, Pages 337-350

  Croom, Katherine F ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CIMETIDINE; DICLOFENAC; DIGOXIN; DOXAZOSIN; ENALAPRIL; FINASTERIDE; FUROSEMIDE; NIFEDIPINE; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; THEOPHYLLINE; WARFARIN;

AGING; ASTHENIA; CATHETER ABLATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EJACULATION DISORDER; FALLING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; HYPOTENSION; IMPOTENCE; MICROWAVE THERAPY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RHINITIS; SABAL; SOMNOLENCE; TRANSURETHRAL RESECTION; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION;

EID: 7044249541     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200412050-00005     Document Type: Review

References (104)

1. Kirby RS, McConnell JD. Fast facts - benign prostatic hyperplasia. 2nd ed. Oxford, UK: Health Press, 1997
2. American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug; 170 (2 Pt 1): 530-47
3. 1-adrenoceptors in the aetiology of LUTS. European Urology Supplements 2002; 1: 5-13
4. Gerber GS. Benign prostatic hyperplasia in older men. Clin Geriatr Med 1998 May; 14 (2): 317-31
5. Barry MJ, Fowler Jr FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997 Jan; 157: 10-5
6. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep; 132: 474-9
7. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 Jul; 150: 85-9
8. de la Rosette J, Alivizatos G, Madersbacher S, et al. European Association of Urology guidelines on benign prostatic hyperplasia [online]. Available from URL: http://www.uroweb.org [Accessed 2004 Apr 2]
9. Garraway WM, Kirby RS. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions. Urology 1994 Nov; 44 (5): 629-36
10. Trueman P, Hood SC, Nayak USL, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999 Mar; 83: 410-5
11. Boyle P, Robertson C, Mazzetta C, et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int 2003 Oct; 92 (6): 575-80
12. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002 Feb; 59 (2): 245-50
13. Wasson JH, Bruskewitz RC, Elinson J, et al. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 1993 Nov; 150: 1696-700
14. Smith MD, McGhan WF. The prostate's economic squeeze. Bus Health 1997 Jul; 15 (7): 40, 42
15. O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003 Sep; 62 (3 Suppl. 1): 15-23
16. Azam U, Castleden M, Turner D. Economics of lower urinary tract symptoms (LUTS) in older people. Drugs Aging 2001; 18 (3): 213-23
17. Foley CL, Taylor C, Kirby RS. Counting the cost of treating benign prostatic hyperplasia. BJU Int 2004 Feb; 93 (3): 250-2
18. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia: clinical and economic considerations. Pharmacoeconomics 2001; 19 (2): 131-53
19. Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995 Oct; 46 (4): 477-83
20. Albertsen PC, Pellissier JM, Lowe FC, et al. Economic analysis of finasteride: a model-based approach using data from the Proscar® Long-Term Efficacy and Safety Study. Clin Ther 1999 Jun; 21 (6): 1006-24
21. Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996 May; 9 (5): 443-54
22. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004; 45: 411-9
23. Brown CT, Das G. Assessment, diagnosis and management of lower urinary tract symptoms in men. Int J Clin Pract 2002 Oct; 56 (8): 591-603
24. Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic hyperplasia. Am Fam Physician 2002 Jul 1; 66 (1): 77-84
25. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999; 83: 227-37
26. Yang Q, Peters TJ, Donovan JL, et al. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol 2001 May; 165: 1526-32
27. Hoffman RM, MacDonald R, Slaton JW, et al. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003 Jan; 169: 210-5
28. Collins MM, Barry MJ, Bin L, et al. Diagnosis and treatment of benign prostatic hyperplasia: practice patterns of primary care physicians. J Gen Intern Med 1997 Apr; 12: 224-9
29. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62 (1): 135-67
30. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999 Jul; 36 (1): 1-13
31. McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62 (4): 633-53
32. 1A-adrenergic antagonist. Urology 1998; 51 (6): 861-72
33. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 2003 Sep; 62 Suppl. 3A: 6-14
34. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003 Aug; 170 (2 Pt 1): 498-502
35. de la Rosette JJ, Kortmann BB, Rossi C, et al. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002 Apr; 167 (4): 1734-9
36. Schulman CC, Lock TMTW, Buzelin J-M, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. Members of the European Tamsulosin Study Group. J Urol 2001 Oct; 166: 1358-63
37. O'Leary M. Tamsulosin demonstrates long-term efficacy on multiple clinical and quality-of-life scoring systems [abstract no. 414]. Eur Urol 2002 Jan; 1 Suppl. 1: 106
38. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. The Terazosin Research Group. Urology 1995 Mar; 45 (3): 406-13
39. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997 Feb; 157: 525-30
40. Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction - what's the long-term effectiveness of medical therapies? Eur Urol 2001; 39 Suppl. 3: 20-5
41. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. N Engl J Med 2003 Dec 18; 349 (25): 2387-98
42. Chess-Williams R. The use of α-adrenoceptor antagonists in lower urinary tract disease. Expert Opin Pharmacother 2002 Feb; 3 (2): 167-72
43. Sanofi-Synthelabo. Xatral® prescribing information (UK). 2003 Mar [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 22]
44. Sanofi-Synthelabo. Xatral® XL 10mg prescribing information (UK). 2003 Oct [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 22]
45. Sanofi-Synthelabo Inc. Uroxatral® (alfuzosin HCl extended-release tablets) prescribing information (US). 2003 Jun [online]. Available from URL: http:www.sanofi-synthelabous.com [Accessed 2004 Apr 22]
46. Medical Products Agency Sweden. Summary of product characteristics: Xatral. 2004 Jul 16 [online]. Available from URL: http://www.mpa.se [Accessed 2004 Jul 27]
47. Pfizer Limited. Cardura™ prescribing information (UK). 2003 Nov [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 22]
48. Pfizer Limited. Cardura™ XL 4mg, Cardura™ XL 8mg prescribing information (UK). 2001 Aug [online]. Available from URL: http://www.emc. medicines.org.uk [Accessed 2004 Apr 22]
49. Pfizer Inc. Cardura® (doxazosin mesylate) tablets prescribing information (US). 2001 Oct [online]. Available from URL: http://www.pfizer.com [Accessed 2004 Apr 22]
50. Boehringer Ingelheim Pharmaceuticals Inc. Flomax® (tamsulosin hydrochloride) capsules prescribing information [online]. Available from URL: http://www.us.flomax-bph.com [Accessed 2004 Apr 22]
51. Yamanouchi Pharma Ltd. Flomax® MR prescribing information (UK). 2001 Sep 13 [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 6]
52. Yamanouchi Pharmaceutical Co. Ltd. Harnal® capsules 0.1mg, Harnal® capsules 0.2mg (tamsulosin hydrochloride) prescribing information (Japan). 2003 Dec [online]. Available from URL: http://ns.e-search.ne.jp/~jpr/ [Accessed 2004 Apr 14]
53. Abbott Laboratories Limited. Hytrin® 1, 2, 5 & 10 mg tablets prescribing information (UK). 2001 Feb [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Apr 22]
54. Abbott Laboratories. Hytrin®(terazosin hydrochloride) capsules prescribing information (US) 2001 Feb [online]. Available from URL: http://www.rxabbott.com [Accessed 2004 Apr 22]
55. Peters DH, Sorkin EM. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993 Jul; 46 (1): 177-208
56. Ekman P. Maximum efficacy of finastride is obtained within 6 months and maintained over 6 years. The Scandinavian Finasteride Study Group. Eur Urol 1998; 33: 312-7
57. Evans HC, Goa KL. Dutasteride. Drugs Aging 2003; 20 (12): 905-16
58. Dvorkin L, Song KY. Herbs for benign prostatic hyperplasia. Ann Pharmacother 2002 Sep; 36: 1443-52
59. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998 Nov 11; 280 (18): 1604-9
60. Boyle P, Robertson C, Lowe F, et al. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533-9
61. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 May; 41 (5): 497-506; discussion 506-7
62. Speakman MJ. Disease managemem programs to promote early diagnosis and treatment of benign prostatic hyperplasia. Dis Manage Health Outcomes 2003; 11 (1): 7-10
63. Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000 Feb; 34 (2): 188-99
64. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic Obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995 Sep; 76 (3): 325-36
65. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenler placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900
66. Narayan P, Tewari A. A second phase III multicenler placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostalic hyperplasia. Members of United States 93-01 Study Group. J Urol 1998 Nov; 160: 1701-6
67. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther 2000 Nov/Dec; 17 (6): 287-300
68. 1- blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12
69. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003 Jan; 91 (1): 41-4
70. Abrams P, Speakman M, Stott M, et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997 Oct; 80 (4): 587-96
71. 1A-adrenoceptor antagonist. Eur Urol 1996; 29: 155-67
72. Kawabe K, Ueno A, Takimoto Y, et al. Clinical evaluation of YM617 on bladder outlet obstruction associated with benign prostatic hyperptrophy - a double-blind, multicentre study compared with placebo. Japanese Journal of Urological Surgery 1991; 4(2); 231-42
73. Kawabe K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 1995; 76 Suppl. 1: 63-7
74. Michel MC, Mehlburger L, Bressel H-U, et al. Comparison of tamsulosin efficacy in subgroups of patients with urinary tract symptoms. Prostate Cancer Prostatic Dis 1998; 1: 332-5
75. Lowe FC. Efficacy and tolerability of tamsulosin in patients <65 years and ≥65 years with benign prostatic hyperplasia [abstract no. 1033]. J Urol 1999; 161 (4 Suppl.): 267
76. Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000 Jun; 163: 1725-9
77. Batista JF, Palacio A, Torrubia R, et al. Tamsulosin: does co-morbidity affect outcomes? [abstract no. P1.4.12]. BJU Int 2000 Nov; 86 Suppl. 3: 30
78. Lepor H, for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901-6
79. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999 Dec; 36 (6): 609-20
80. Speakman M. Tamsulosin reduces the risk of acute urinary retention [abstract no. 1492]. J Urol 2002 Apr; 167 Suppl.: 375
81. Farmer R, John L, Clifford G. The effectiveness of medical treatments in delaying the need for surgery amongst men with LUTS/BPH - a population study [abstract no. P-1.2.13]. BJU Int 2002; 90 Suppl. 2: 15
82. Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obslruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 597-605
83. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997 Oct; 80 (4): 606-11
84. 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med 1998; 29 (5-6): 289-304
85. Okada H, Kamidono S, Yoshioka T, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000 Apr; 85 (6): 676-81
86. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003; (1): CD002081
87. Lowe F, Narayan P, Djavan B. Prospective, randomised, multicentre trial to evaluate the rapidity of onset and side effect profile of tamsulosin (TAM) vs terazosin (TER) in men with benign prostatic hyperplasia (BPH) [abstract no. 421]. Eur Urol 2002; 1 Suppl. 1: 108
88. Lee E. Comparison of tamsulosin and finasteride for lower urinary trad symptoms associated with benign prostatic hyperplasia in Korean patients. J Int Med Res 2002 Nov-Dec; 30 (6): 584-90
89. Michel MC, Neumann HG, Mehlburger L, et al. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? BJU Int 2001 Jan; 87(1): 31-4
90. Höfner K, Claes H, De Reijke TM, et al. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. The European Tamsulosin Study Group. Eur Urol 1999 Oct; 36 (4): 335-41
91. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003 Sep; 62 (3 Suppl. 1): 24-33
92. Narayan P, Lowe FC. The effects of tamsulosin on vital signs in two multicenter, placebo-controlled studies. Cardiovasc Rev Rep 2000 Sep; 21: 494-5
93. Yasukawa K, Miyazawa Y, Tajima Y. Investigation of the effects of tamsulosin on blood pressure in normotensive, controlled hypertensive, and uncontrolled hypertensive men with benign prostatic hyperplasia. Journal of Health Science 2001; 47 (2): 192-202
94. Michel MC, Mehlburger L, Bressel H-U, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? [Erratum in: J Urol 1998 Dec; 160: 2164]. J Urol 1998 Sep; 160: 784-91
95. Michel MC, Mehlburger L, Bressel H-U, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? [Erratum in: J Urol 1998 Dec; 160: 2164]. J Urol 1998 Sep; 160: 784-91
96. 1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects. J Int Med Res 2001; 29: 236-51
97. de Mey C, Michel MC, McEwen J, et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 481-8
98. Lowe F, Djavan B. Prospective, randomized trial to evaluate the side effect profile of tamsulosin vs terazosin in 1983 men with benign prostatic hyperplasia. J Urol 2002 Apr; 167 Suppl.: 267
99. de Mey C, Terpstra I. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning [abstract no. 978]. J Urol 2000 Apr; 163 (4 Suppl.): 220
100. Batista JE, Palacio A, Torrubia R, et al. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real life practice in Spain. Arch Esp Urol 2002 Jan-Feb; 55 (1): 97-105
101. Ohsfeldt RL, Kreder KJ, Klein RW, et al. Cost-effectiveness of tamsulosin, doxazosin and terazosin in the treatment of benign prostatic hyperplasia [abstract no. DP27]. J Urol 2003 Apr; 169 Suppl.: 345
102. Girts TK, Meyer JW, Shah H. Total health care costs for benign prostatic hyperplasia patients on alpha(1)-blocker treatment in a managed care setting [abstract no. PSD3]. Value Health 2004 May-2004 30; 7: 362 plus poster
103. Botteman MF, Lowe FC, Naslund M, et al. A cost comparison analysis of two clinically uroselective alpha blockers in the treatment of benign prostatic hyperplasia [abstract no. PUK2]. Value Health 2004 May-Jun 30; 7; 363 plus poster.
104. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19 (4): 730-42